
Astria Therapeutics Inc ATXS.OQ ATXS.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Astria Therapeutics Inc is for a loss of 48 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.1% in the last three months.
Wall Street's median 12-month price target for Astria Therapeutics Inc is $27.00, above its last closing price of $6.47.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.45 | -0.45 | -0.20 | Beat | 55.7 |
Sep. 30 2024 | -0.44 | -0.42 | -0.42 | Met | 0.4 |
Jun. 30 2024 | -0.39 | -0.38 | -0.43 | Missed | -11.7 |
Mar. 31 2024 | -0.37 | -0.36 | -0.38 | Missed | -4.4 |
Dec. 31 2023 | -0.78 | -0.78 | -0.94 | Missed | -20.5 |
Sep. 30 2023 | -0.46 | -0.49 | -0.63 | Missed | -29.6 |
Jun. 30 2023 | -0.49 | -0.49 | -0.45 | Beat | 7.6 |
Mar. 31 2023 | -0.57 | -0.55 | -0.40 | Beat | 27.5 |
This summary was machine generated March 12 at 20:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)